Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations.

Anthony Tarabay,Alice Boileve,Cristina Smolenschi,Leony Antoun,Marine Valery,Alina Fuerea,Audrey Perret,Pascal Burtin,Simona Cosconea,Hichem Belkhodja,David Malka,Valérie Boige,Antoine Hollebecque,Michel Ducreux

Biomedicines（2023）

Cited 0|Views33

No score

Abstract

Actionable GAs were found in more than a quarter of patients with advanced PDAC. Overall, targeting actionable GAs with MTTs was not associated with improved OS in this retrospective study with limited patient numbers. However, selected GA/MTT combinations (e.g., BRCA mutations/olaparib) were associated with a better outcome.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined